TY - JOUR
T1 - TGFBR1*6A may contribute to hereditary colorectal cancer
AU - Bian, Yansong
AU - Caldes, Trinidad
AU - Wijnen, Juul
AU - Franken, Patrick
AU - Vasen, Hans
AU - Kaklamani, Virginia
AU - Nafa, Khédoudja
AU - Peterlongo, Paolo
AU - Ellis, Nathan
AU - Baron, John A.
AU - Burn, John
AU - Moeslein, Gabriela
AU - Morrison, Patrick J.
AU - Chen, Yu
AU - Ahsan, Habibul
AU - Watson, Patrice
AU - Lynch, Henry T.
AU - De La Chapelle, Albert
AU - Fodde, Riccardo
AU - Pasche, Boris
PY - 2005
Y1 - 2005
N2 - Purpose: TGFBR1*6A is a tumor susceptibility gene that increases breast, colon, and ovarian cancer risk. Fourteen percent of the general population carries TGFBR1*6A, and TGFBR1*6A homozygotes have a greater than 100% increased colon cancer risk compared with noncarriers. Low-penetrance genes such as TGFBR1*6A may account for a sizable proportion of familial colorectal cancer occurrences. To test this hypothesis, we determined whether TGFBR1*6A contributes to a proportion of mismatch repair (MMR) gene mutation-negative hereditary nonpolyposis colorectal cancer (HNPCC) patients. Patients and Methods: A case-case study was performed of 208 index patients with HNPCC meeting the Amsterdam criteria. Patients were examined for mutations and genomic rearrangements in the MLH1, MSH2, and MSH6 genes and genotyped for TGFBR1*6A. Tumor microsatellite instability status was available for 95 patients. Results: A total of 144 patients (69.2%) carried a deleterious mutation and were classified as positive for MMR gene mutation; 64 patients (30.8%) had no evidence of mutations and were classified as MMR negative. TGFBR1*6A allelic frequency was significantly higher among MMR-negative patients (0.195) than among MMR-positive patients (0.104; P = .011). The proportion of TGFBR1*6A homozygotes was nine-fold higher among MMR-negative (6.3%) than among MMR-positive patients (0.7%; P = .032). The highest TGFBR1*6A allelic frequency was found among MMR-negative patients with tumors exhibiting no microsatellite instability (0.211), and the lowest frequency was found among MMR-positive patients with tumors exhibiting microsatellite instability (0.121); the difference was not statistically significant (P = .17). Conclusion: TGFBR1*6A may be causally responsible for a proportion of HNPCC occurrences.
AB - Purpose: TGFBR1*6A is a tumor susceptibility gene that increases breast, colon, and ovarian cancer risk. Fourteen percent of the general population carries TGFBR1*6A, and TGFBR1*6A homozygotes have a greater than 100% increased colon cancer risk compared with noncarriers. Low-penetrance genes such as TGFBR1*6A may account for a sizable proportion of familial colorectal cancer occurrences. To test this hypothesis, we determined whether TGFBR1*6A contributes to a proportion of mismatch repair (MMR) gene mutation-negative hereditary nonpolyposis colorectal cancer (HNPCC) patients. Patients and Methods: A case-case study was performed of 208 index patients with HNPCC meeting the Amsterdam criteria. Patients were examined for mutations and genomic rearrangements in the MLH1, MSH2, and MSH6 genes and genotyped for TGFBR1*6A. Tumor microsatellite instability status was available for 95 patients. Results: A total of 144 patients (69.2%) carried a deleterious mutation and were classified as positive for MMR gene mutation; 64 patients (30.8%) had no evidence of mutations and were classified as MMR negative. TGFBR1*6A allelic frequency was significantly higher among MMR-negative patients (0.195) than among MMR-positive patients (0.104; P = .011). The proportion of TGFBR1*6A homozygotes was nine-fold higher among MMR-negative (6.3%) than among MMR-positive patients (0.7%; P = .032). The highest TGFBR1*6A allelic frequency was found among MMR-negative patients with tumors exhibiting no microsatellite instability (0.211), and the lowest frequency was found among MMR-positive patients with tumors exhibiting microsatellite instability (0.121); the difference was not statistically significant (P = .17). Conclusion: TGFBR1*6A may be causally responsible for a proportion of HNPCC occurrences.
UR - http://www.scopus.com/inward/record.url?scp=21144448326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=21144448326&partnerID=8YFLogxK
U2 - 10.1200/JCO.2005.00.281
DO - 10.1200/JCO.2005.00.281
M3 - Article
C2 - 15860866
AN - SCOPUS:21144448326
SN - 0732-183X
VL - 23
SP - 3074
EP - 3078
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 13
ER -